United Therapeutics | UTHR - Equity Capital And Reserves


United Therapeutics reported $6.4B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Amarin USD 443.62M 5.8M Jun/2026
Ardelyx USD 148.62M 18.33M Mar/2026
Baxter International USD 6.21B 163M Jun/2026
Bayer EUR 28.85B 2.9B Mar/2026
BioCryst Pharmaceuticals USD -454.29M 99.55M Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Emergent BioSolutions USD 649.3M 47.9M Dec/2023
Gilead Sciences USD 11.74B 11.77B Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Insmed USD 704.85M 34.12M Mar/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
J&J USD 84.97B 3.78B Jun/2026
Lexicon Pharmaceuticals USD 202.86M 95.32M Mar/2026
Moderna USD 6.76B 647M Jun/2026
Omeros USD -228.68M 15.13M Jun/2025
Pfizer USD 85.19B 4.91B Jun/2026
PTC Therapeutics USD -165.36M 15.1M Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
Teva Pharmaceutical Industries USD 7.75B 475M Jun/2026
United Therapeutics USD 6.4B 499.2M Jun/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026